Method for retarding or precluding Alzheimer's dementia

a technology for alzheimer's and dementia, applied in the field of methods for preventing or retarding alzheimer's dementia, can solve the problems of not being able to remove the circulating autoantibodies associated with these proteins, and achieve the effects of reducing cognitive ability, reducing the rate of disease progression, and strengthening the effectiveness of pharmaceutical agents

Inactive Publication Date: 2006-06-22
JACKOWSKI GEORGE +1
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0029] The advantages which flow from the use of biological markers as treatment targets include strengthening the effectiveness of pharmaceutical agents, and assisting in slowing down the rate of disease progression.
[0030] Accordingly, it is an objective of the instant invention to provide a process effective for delaying, reducing and / or retarding the initiation of phagocytosis of astrocytic cells, which process has been linked to loss of cognitive ability associated with the progression of Alzheimer's disease.
[0032] It is a still further objective of the instant invention to provide an immunoassay effective for the recognition of autoantibodies linked to the progression or manifestation of Alzheimer's dementia.

Problems solved by technology

In addition, it has not been previously suggested to remove the circulating autoantibodies associated with these proteins to alleviate symptoms of the disease state.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for retarding or precluding Alzheimer's dementia
  • Method for retarding or precluding Alzheimer's dementia
  • Method for retarding or precluding Alzheimer's dementia

Examples

Experimental program
Comparison scheme
Effect test

experiment # 1

Experiment #1

[0047] CCF-STTG1 cells (brain astrocytes that are GFAP +ve) are co-cultured with RAW cells (macrophage cell line) in the presence of, or without mouse anti-GFAP antibodies. Astrocytes are incubated with anti-GFAP Ab for 10 minutes and then the macrophages are added after and left to incubate for 30 min.

Results:

[0048] Without the Ab, the macrophages are not associated with the astrocytes, but in the presence of anti-GFAP antibodies the macrophages are clumped around the astrocytes. This initiates the phagocytosis process.

experiment # 2

Experiment #2

[0049] CCF-STTG1 cells (brain astrocytes that are GFAP +ve) are co-cultured with RAW cells (macrophage cell line) in the presence of normal serum or AD serum. Astrocytes are incubated with serum for 10 minutes and then the macrophages are added after and left to incubate for 30 min.

[0050] With normal serum, the macrophages are not associated with the astrocytes, but with AD serum the macrophages are clumped around the astrocytes. This demonstrates the start of phagocytosis and attack of the brain cells.

[0051] As seen in FIG. 3, CCF-STTG1 astrocyte cells (arrowhead) and RAW macrophages (arrows) were co-cultured in the presence of a non-specific antibodies mixture (C-D) or anti-human GFAP antibody (E-F) or absence of antibodies (A-B). Binding of macrophages to astrocytes before wash is shown in A-C-E, and interactions remaining after wash in B-D-F. Specific binding occurs only in the presence of antibody specific to GFAP protein.

[0052] Thus, removal or reduction of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
computed tomographyaaaaaaaaaa
CTaaaaaaaaaa
Login to view more

Abstract

A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), from the sera of a patient in an amount effective to reduce or eliminate phagocytosis of astrocytic cells. The invention further includes a process of immune system modulation effective for autoantibody removal.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 334,701, filed Dec. 30, 2002, which is a continuation-in-part of U.S. patent application Ser. No. 09 / 859,559, filed on May 16, 2001, the entire contents of which is incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to a method useful in treating a condition related to the development of Alzheimer's disease (AD). The invention particularly relates to a process retarding or precluding Alzheimer's dementia by reducing or eliminating the concentration of at least one auto-antibody whose presence has been shown to initiate phagocytosis of astrocytic cells, thereby leading to Alzheimer's disease. BACKGROUND OF THE INVENTION [0003] Alzheimer's disease, also referred to as Alzheimer's dementia or AD is a progressive neurodegenerative disorder that causes memory loss and serious mental deterioration. Diagnosticians have long sough...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61M1/36C12Q1/32G01N33/564G01N33/68
CPCA61M1/3679C12Q1/32G01N33/564G01N33/6896G01N2800/2821
Inventor JACKOWSKI, GEORGEFURESZ, SHIRLEY
Owner JACKOWSKI GEORGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap